{"filings":[{"id":1195757,"accession_number":"0001193125-26-277579","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2026-06-22T20:30:15+00:00","items":["5.07"],"status":"ready","headline":"PepGen stockholders elect three Class I directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Howard Mayer, M.D. elected with 36.1M votes for, 8.5M withheld; Joshua Resnick and Lisa Wyman also elected.","Ratification of KPMG as independent auditor for FY 2026 approved with 54.6M votes for vs. 77K against.","Quorum of 54.7M shares present out of 69.2M outstanding at June 18, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":563843,"accession_number":"0001193125-26-233403","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2026-05-21T11:30:11+00:00","items":["7.01","9.01"],"status":"ready","headline":"PepGen updates corporate presentation for IDMC meeting; no specific news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["PepGen to present at 15th International Myotonic Dystrophy Consortium (May 26-30, 2026).","Updated corporate presentation furnished as Exhibit 99.1 on May 21, 2026.","Filing does not include financial results, clinical data, or guidance changes.","No material new information beyond the presentation itself was provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40402,"accession_number":"0001193125-26-219424","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2026-05-12T20:10:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"PepGen Q1 net loss $17.8M; cash $132.3M; 10 mg/kg DM1 cohort fully enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.8M ($0.26 per share) vs $30.2M loss in Q1 2025; R&D spend down to $13.0M from $25.4M.","Cash, equivalents and marketable securities $132.3M; funding seen into 2H 2027.","FREEDOM2-DM1 5 mg/kg cohort showed favorable safety, splicing and vHOT trends; 10 mg/kg cohort fully enrolled with data expected 2H 2026.","FDA partial clinical hold on FREEDOM2 relates to preclinical studies; timing of ongoing trial not impacted.","13 patients enrolled in open-label extension at 5 mg/kg with no discontinuations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109531,"accession_number":"0001193125-26-131786","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PepGen reports positive Phase 2 FREEDOM2 data for PGN-EDODM1 in DM1; splicing correction 22.9% ex-outlier","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5 mg/kg cohort (n=8): mean splicing correction 7.3% overall, 22.9% excluding outlier; placebo 6.8%.","No serious adverse events; all TEAEs mild/moderate; nausea most common; no renal toxicity.","Middle finger vHOT showed improvement trend vs placebo worsening; returned to baseline at Week 16.","10 mg/kg cohort >50% enrolled; data expected 2H 2026; cash sufficient into 2H 2027.","Mean muscle PGN-EDODM1 concentration 158 ng/g in 5 of 6 treated patients (one pending)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109530,"accession_number":"0001193125-26-091784","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PepGen furnishes updated corporate presentation for March 2026; no specific financial or operational details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Regulation FD to update corporate presentation (Exhibit 99.1).","No new financial results, data readouts, or guidance changes are included in the furnished materials.","The company provided only a presentation title without accompanying slide content in this filing.","Investors are directed to the company's website for the full presentation details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109529,"accession_number":"0001193125-26-091503","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"PepGen reports FY2025 net loss $89.7M; FDA partial hold on FREEDOM2 trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed partial clinical hold on FREEDOM2-DM1 Phase 2 trial of PGN-EDODM1; questions relate to preclinical studies, not clinical data.","Dosing of 10 mg/kg cohort continues in Canada and UK; no US patients enrolled. 5 mg/kg data expected Q1 2026, 10 mg/kg data 2H 2026.","Cash and marketable securities $148.5M as of Dec 31, 2025, sufficient into H2 2027. Net loss $89.7M for FY2025 ($2.12 per share).","Appointed Joseph Vittiglio as Chief Business and Legal Officer in December 2025.","USPTO issued composition-of-matter patent for PGN-EDODM1, providing US exclusivity into H2 2042."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126059,"accession_number":"0001193125-25-310544","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen appoints Joseph Vittiglio as Chief Business and Legal Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Vittiglio named Chief Business and Legal Officer, effective December 8, 2025.","He brings 20+ years of biotech legal, compliance, and business development experience.","Most recently served as Chief Business and Legal Officer at bluebird bio.","At bluebird, he helped launch 3 gene therapies and completed over $400M in financings.","He previously led legal and business functions at Finch Therapeutics and AMAG Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126058,"accession_number":"0001193125-25-276019","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PepGen reports Q3 net loss of $18.0M; 53.7% splicing correction in DM1 Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FREEDOM-DM1 15 mg/kg showed mean splicing correction of 53.7%, highest reported in DM1 patients.","All patients in FREEDOM2 5 mg/kg cohort enrolled; topline data expected Q1 2026.","Closed $115M public offering in Sept 2025; cash runway extended into H2 2027.","Net loss $18.0M ($0.52/sh) vs $21.4M ($0.66/sh) in Q3 2024; cash $163.7M at Sept 30.","R&D expense $13.4M down from $17.7M YoY; G&A flat at $5.2M."],"consensus_eps_estimate":-0.5763,"consensus_eps_actual":-2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126057,"accession_number":"0001193125-25-271089","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"PepGen reprices underwater stock options to $4.53 for key employees including CEO, CFO, EVP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repriced 3,557,903 shares held by employees and named executives; new exercise price $4.53.","Eligible participants must remain employed until March 31, 2027 to exercise at reduced price.","Previous exercise prices ranged from $8.89 to $17.91 per share; ~2/3 of all employee options were underwater.","CEO James McArthur recused from board vote; repricing approved by disinterested directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126056,"accession_number":"0001193125-25-226746","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PepGen updates corporate presentation; content not provided in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company provided an updated corporate presentation dated October 2025.","Specific updates such as financial results, pipeline data, or guidance are not included in the filing excerpt.","Investors should review the full presentation on the company's website for any material changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142788,"accession_number":"0001193125-25-218503","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"PepGen Inc. prices $100 million public offering of 31.25 million shares at $3.20 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PepGen entered into underwriting agreement with Leerink Partners and Stifel to sell 31,250,000 shares at $3.20 per share.","Underwriters exercised in full their 30-day option to purchase an additional 4,687,500 shares.","Net proceeds estimated at $107.6 million to fund FREEDOM-DM1 and FREEDOM2-DM1 clinical trials and for working capital.","Offering expected to close on September 26, 2025, subject to customary conditions.","Securities offered under an effective shelf registration statement filed with the SEC on June 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142787,"accession_number":"0001193125-25-215435","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PepGen reports 53.7% mean splicing correction in DM1 patients at 15 mg/kg dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean splicing correction of 53.7% at 15 mg/kg (n=6) by 22-gene panel at Day 28; all 6 patients responded.","PGN-EDODM1 well-tolerated; no serious treatment-related AEs, all mild/moderate, transient, resolved without intervention.","Dose-proportional muscle concentration increase vs 5 mg/kg (12.3%) and 10 mg/kg (29.1%) cohorts.","FREEDOM2 MAD study 5 mg/kg cohort data expected Q1 2026; 10 mg/kg cohort dosing to begin Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142786,"accession_number":"0001193125-25-174982","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PepGen completes dosing in 15 mg/kg cohort of FREEDOM-DM1; net loss narrows to $23.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["On track to report topline safety and splicing data from 15 mg/kg cohort in early Q4 2025.","Concluding FREEDOM trial after 15 mg/kg cohort; transitioning sites to Phase 2 MAD study FREEDOM2-DM1.","Cash $74.7M sufficient into Q2 2026; net loss $23.1M ($0.70/sh) vs $28.3M ($0.87/sh) YoY.","Appointed Kasra Kasraian, PhD, as Chief Technology Officer in May 2025.","FREEDOM2 5 mg/kg cohort results expected Q1 2026."],"consensus_eps_estimate":-0.8441,"consensus_eps_actual":-1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160865,"accession_number":"0000950170-25-082707","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PepGen stockholders elect three Class III directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Mitchell H. Finer elected with 27,224,040 votes for; 2,082,233 broker non-votes.","Heidi Henson elected with 27,219,131 for; 124,312 withheld; same broker non-votes.","Laurie B. Keating elected with 22,160,152 for; 5,183,291 withheld.","KPMG ratified as auditor: 29,423,817 for, 1,821 against, 38 abstentions; zero broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160864,"accession_number":"0000950170-25-078428","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PepGen discontinues DMD program after PGN-EDO51 misses dystrophin target; shifts focus to DM1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10 mg/kg PGN-EDO51: total dystrophin only 0.59% of normal (mean increase 0.36%); exon skipping +3.5%.","Company voluntarily discontinuing PGN-EDO51 and winding down all DMD research & development.","DM1 program prioritized; FREEDOM-DM1 15 mg/kg data expected H2 2025, FREEDOM2-DM1 5 mg/kg data Q1 2026.","PGN-EDO51 safety favorable; all treatment-related AEs mild, no serious adverse events.","Prior DM1 data (10 mg/kg single dose) showed 29% mean mis-splicing correction at safety update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160863,"accession_number":"0000950170-25-066419","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PepGen Q1 2025 net loss $30.2M; DM1 splicing correction 29.1% at 10 mg/kg","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.2M ($0.92/share) in Q1 2025 vs. $18.0M ($0.63/share) in Q1 2024.","Cash and marketable securities $97.8M as of March 31, 2025; runway at least 12 months.","Positive DM1 data: mean splicing correction of 29.1% 28 days after single 10 mg/kg dose of PGN-EDODM1.","CONNECT1-EDO51 10 mg/kg dystrophin data expected Q3 2025; CONNECT2 trial voluntarily paused.","Board added Lisa Wyman and Mitchell H. Finer, PhD in March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179064,"accession_number":"0000950170-25-047690","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"PepGen expands board to eight with appointments of Finer and Wyman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mitchell Finer (PhD), former CSO at bluebird bio, and Lisa Wyman, CTO at Scholar Rock, join board.","Board expands from six to eight; Finer Class III director, Wyman Class I director.","Each receives initial option award of 26,000 shares, vesting over three years.","Standard non-employee director compensation and indemnification agreements apply.","CEO cites their expertise in scaling manufacturing and gene therapy development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179063,"accession_number":"0000950170-25-046746","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"PepGen CMO Michelle Mellion resigns, effective April 4, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michelle L. Mellion, MD, resigned as Chief Medical Officer; departure effective April 4, 2025.","Resignation is not due to any disagreement with the company, per the 8-K.","No successor has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179062,"accession_number":"0000950170-25-031337","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen voluntarily pauses Phase 2 CONNECT2-EDO51 study; awaits 10 mg/kg data from CONNECT1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Temporarily pauses CONNECT2-EDO51 in DMD until review of 10 mg/kg data from ongoing CONNECT1-EDO51 study.","No new safety issues observed in PGN-EDO51 program since safety update on January 23, 2025.","CONNECT1 10 mg/kg cohort fully enrolled; data expected in third quarter of 2025.","Resources focused on completing CONNECT1 and advancing FREEDOM-DM1 studies in myotonic dystrophy type 1.","CEO states pause allows gathering additional safety data and potential improvement of CONNECT2 design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179061,"accession_number":"0000950170-25-025232","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PepGen reports robust splicing correction in DM1 trial; 29.1% mean correction at 10 mg/kg single dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean splicing correction of 12.3% (5 mg/kg, n=6) and 29.1% (10 mg/kg, n=4) at 28 days post single dose.","Favorable emerging safety profile; one treatment-related SAE of abdominal pain potentially confounded.","Cash $120.2M as of Dec 31, 2024, expected to fund operations into 2026.","Net loss $90.0M for FY2024 ($2.85/share) vs $78.6M ($3.30/share) in FY2023.","15 mg/kg cohort results expected H2 2025; CONNECT1-EDO51 10 mg/kg fully enrolled with results Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179060,"accession_number":"0000950170-25-010515","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen gets FDA clinical hold on CONNECT2 U.S. trial; Health Canada restricts dose escalation in CONNECT1","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["10 mg/kg cohort fully enrolled (n=4); data expected year-end 2025.","One participant had eGFR reduction; dosing paused, eGFR improving.","Health Canada allows continued dosing at current levels but requests additional info before escalation.","FDA placed clinical hold on U.S. CONNECT2 trial; company working to address agency questions.","All treatment-related adverse events mild per Jan 23, 2025 update by CMO Paul Streck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195756,"accession_number":"0000950170-24-136389","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen receives FDA clinical hold for Phase 2 DMD trial IND","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued clinical hold for IND to initiate CONNECT2-EDO51 Phase 2 study of PGN-EDO51 in DMD patients.","FDA to provide official clinical hold letter within 30 days; CONNECT2 remains open in the UK.","Open-label CONNECT1-EDO51 study in Canada continues; 10 mg/kg cohort now fully enrolled.","PepGen intends to work closely with FDA to address questions expeditiously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195755,"accession_number":"0000950170-24-122815","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PepGen Q3 net loss $21.4M; cash $138.9M; DM1/DMD trial updates expected 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.4M ($0.66 per share) vs $23.3M ($0.98) in Q3 2023.","Cash and equivalents of $138.9M as of Sept 30, 2024, funding operations into 2026.","R&D expense $17.7M (down 14% YoY); G&A $5.4M (up 29% YoY).","FREEDOM-DM1 5 & 10 mg/kg data expected Q1 2025; 15 mg/kg cohort in H2 2025.","Appointed Paul Streck, MD, MBA, as EVP and Head of R&D in August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195754,"accession_number":"0000950170-24-113410","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen reports favorable safety profile for PGN-EDO51 in Phase 2 DMD trial at WMS Congress","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CONNECT1-EDO51 safety data as of Oct 3: no serious adverse events; all treatment-related AEs mild and resolved.","One hypomagnesemia case resolved with oral supplementation; no discontinuations, dose interruptions or reductions.","Presenting short oral and five posters on PGN-EDO51 (DMD) and PGN-EDODM1 (DM1) at WMS Congress in Prague Oct 8-12.","Nonclinical data for both programs and FREEDOM-DM1 trial design also featured in poster sessions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212027,"accession_number":"0000950170-24-108126","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PepGen board member Christopher Ashton to retire effective Sept 30; board size reduced to 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Ashton, PhD, voluntarily resigns from board, effective Sept 30, 2024; also leaves audit and compensation committees.","Board size reduced from seven to six directors immediately following resignation.","Director Habib J. Dable appointed to audit committee as of Sept 30, 2024.","Ashton cites desire to focus on guiding pre-IPO companies; no disagreement with company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212026,"accession_number":"0000950170-24-098860","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen appoints Paul Streck, M.D., MBA as EVP, Head of Research & Development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appoints Paul Streck, M.D., MBA as EVP, Head of R&D effective immediately, joining PepGen Executive Team.","Streck brings >20 yrs drug development experience; previously CMO at Albireo, Arena, Alder, Insmed, and roles at GSK, Shire, Amgen.","His accomplishments include five IND approvals, six global regulatory launches, nine commercial product launches.","CEO James McArthur cites Streck's value as PepGen advances four active clinical trials and preclinical pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212025,"accession_number":"0000950170-24-093348","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PepGen reports Q2 2024 net loss $28.3M; PGN-EDO51 shows 2.15% exon skipping in CONNECT1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $28.3M ($0.87/sh) for Q2 2024 vs $19.5M ($0.82/sh) YoY; cash $161.3M, runway into 2026.","PGN-EDO51 (DMD) 5mg/kg cohort: mean exon skipping 2.15%, dystrophin increase 0.70% (muscle-adjusted) from baseline; well tolerated.","FREEDOM-DM1 Phase 1 results expected Q4 2024; FREEDOM2-DM1 cleared by Health Canada & MHRA, dosing H2 2024.","PGN-EDO53 (DMD) advancing in IND/CTA-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212024,"accession_number":"0001193125-24-188977","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PepGen announces positive Phase 2 data for PGN-EDO51 in DMD: exon skipping 2.15%, dystrophin increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PGN-EDO51 5 mg/kg achieved mean exon skipping of 2.15% in biceps tissue at week 13 (n=3).","Mean muscle-adjusted dystrophin level of 1.49% of normal, +0.70% from baseline; absolute dystrophin 0.61%, +0.26%.","Drug well tolerated; no discontinuations, one mild AE resolved, no kidney or electrolyte issues.","All three patients continue in long-term extension; 10 mg/kg cohort dosing ongoing with results expected in early 2025.","CONNECT2 Phase 2 trial open in UK; US site expected by year-end; design being optimized based on data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212023,"accession_number":"0000950170-24-080021","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen appoints Afsaneh Mohebbi, Ph.D. as SVP Portfolio & Program Mgmt and Dave Borah, CFA as SVP IR & Corp Comms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Afsaneh Mohebbi, Ph.D. appointed SVP, Portfolio & Program Management; previously consultant to PepGen since Jan 2024.","Dave Borah, CFA named SVP, Investor Relations & Corporate Communications; most recently SVP at Mural Oncology.","Appointments effective immediately; CEO cites expertise as key ahead of clinical milestones in H2 2024.","Mohebbi led Fabry drug Replagal and Firazyr approvals at Shire; Borah increased analyst coverage at Bicycle Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230869,"accession_number":"0001193125-24-164587","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"PepGen stockholders approve officer exculpation amendment and elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved Certificate of Amendment to limit liability of certain officers under Delaware law; effective June 20, 2024.","Elected Class II directors Habib Dable (26,048,824 for) and James McArthur (29,411,307 for) to serve until 2027.","Ratified KPMG LLP as independent auditor for fiscal year ending December 31, 2024 (30,364,851 for).","All proposals passed with substantial majority; quorum of 30,365,425 of 32,390,445 shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230868,"accession_number":"0000950170-24-071617","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen promotes Michelle Mellion to CMO, Hayley Parker to SVP Global Regulatory Affairs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michelle Mellion, M.D., promoted to Chief Medical Officer effective immediately.","Hayley Parker, Ph.D., promoted to Senior Vice President, Global Regulatory Affairs effective immediately.","Mellion joined PepGen as SVP Head of Clinical Development; previously held roles at Fulcrum Therapeutics.","Parker joined PepGen as VP Regulatory Affairs; previously led regulatory strategy at Scholar Rock.","CEO McArthur cites their leadership in driving clinical and regulatory strategies for rare muscle disorders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230867,"accession_number":"0000950170-24-059485","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PepGen Q1 net loss $18.0M, cash $175.2M; key clinical data expected mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $175.2M as of March 31, 2024, funding operations into 2026.","Net loss widened to $18.0M from $16.3M YoY; R&D expense $14.7M, G&A $5.1M.","Preliminary CONNECT1-EDO51 data (5 mg/kg dose) expected mid-2024; FDA orphan/rare pediatric designations granted.","FREEDOM1-DM1 preliminary data from at least 5 mg/kg cohort expected second half 2024.","Raised $86.3M net from February common stock offerings (ATM + underwritten)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249260,"accession_number":"0001193125-24-069110","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"PepGen amends bylaws to update proxy rules and stockholder meeting procedures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Board adopted Second Amended and Restated By-laws effective March 15, 2024.","Updates include universal proxy rule compliance, mandatory white proxy card for non-Board solicitations.","Eliminates requirement to make stockholder list available at meetings per DGCL amendments.","Clarifies exclusive forum for certain legal proceedings in Delaware courts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249259,"accession_number":"0000950170-24-030505","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen receives FDA orphan drug and rare pediatric disease designations for DMD candidate PGN-EDO51","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapy for DMD.","PGN-EDO51 targets DMD patients whose mutations are amenable to exon 51 skipping approach.","Ongoing CONNECT1 Phase 2 trial; CONNECT2 Phase 2 enrollment expected later in 2024.","Orphan designation offers 7-year U.S. exclusivity plus tax credits and fee benefits upon approval.","Rare pediatric disease designation may yield a priority review voucher for a future product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249258,"accession_number":"0000950170-24-027111","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PepGen reports FY2023 net loss $78.6M; cash runway into 2026 after $80M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Enrollment complete for PGN-EDO51 5 mg/kg cohort; preliminary data expected mid-2024.","CONNECT2-EDO51 Phase 2 trial for DMD initiated in UK; designed to support accelerated approval.","FREEDOM-DM1 Phase 1 trial enrolling; preliminary data from 5 mg/kg cohort expected H2 2024.","Cash $110.4M as of Dec 31, 2023; combined with $80M Feb 2024 offering extends runway into 2026.","Net loss $78.6M for FY2023 vs $69.1M in FY2022; R&D expenses $68.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249257,"accession_number":"0000950170-24-024350","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen gets UK MHRA clearance to start Phase 2 trial of PGN-EDO51 for DMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MHRA authorized CTA for CONNECT2-EDO51 Phase 2 trial of PGN-EDO51 in DMD patients amenable to exon 51 skipping.","Trial is randomized, placebo-controlled, multiple ascending dose, enrolling ~20 boys/young men aged ≥6 years.","PGN-EDO51 is an oligonucleotide therapy; data from CONNECT1 (ongoing Phase 1) plus CONNECT2 could support accelerated approval.","Starting dose 5 mg/kg escalating to 10 mg/kg and potentially higher; muscle biopsies at baseline and week 25 to assess exon skipping and dystrophin production.","Participants have option for open-label extension after 24-week treatment period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249256,"accession_number":"0000950170-24-016804","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen gets FDA Fast Track for PGN-EDODM1 in DM1; Phase 1 data due 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track designation for PGN-EDODM1 targeting myotonic dystrophy type 1 (DM1).","No approved therapies target root cause of DM1; PGN-EDODM1 aims to be disease-modifying.","Ongoing FREEDOM-DM1 Phase 1 trial (NCT06204809); preliminary data expected in 2024.","PGN-EDODM1 previously received FDA Orphan Drug Designation in September 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249255,"accession_number":"0001193125-24-025921","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"PepGen prices $80.1M common stock offering of 7.53M shares at $10.635 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$80.1M; net proceeds ~$76.4M after underwriting discounts and expenses.","Offering led by RA Capital Management; 11 institutional investors including Adage, Frazier, Janus.","Net proceeds to fund R&D and clinical development of oligonucleotide therapies; cash runway into 2026.","Offering expected to close February 9, 2024; Leerink Partners sole bookrunner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249254,"accession_number":"0000950170-24-004824","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen appoints Mary Beth DeLena as General Counsel and Secretary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Beth DeLena joins PepGen as General Counsel and Secretary, effective January 17, 2024.","She brings over 20 years of legal experience, most recently 15 years at Alnylam Pharmaceuticals as SVP, Deputy General Counsel.","At Alnylam, she advised on strategic collaborations, licensing, and capital-raising through the company's transition to commercial stage.","PepGen CEO cites her expertise in commercial, regulatory, and policy matters as key to advancing oligonucleotide therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249253,"accession_number":"0000950170-24-002679","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen doses first patient in Phase 2 CONNECT1-EDO51 trial for Duchenne muscular dystrophy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in open-label, multiple ascending dose Phase 2 trial of PGN-EDO51 in DMD patients amenable to exon 51 skipping.","Trial enrolls ~10 male patients aged >=8 years; starting dose 5 mg/kg escalating to 10 mg/kg pending safety.","Preliminary data from the 5 mg/kg cohort expected mid-2024: safety, exon skipping, and dystrophin production.","Phase 1 healthy volunteers showed peak exon 51 skipping of 3.8% after single 10 mg/kg dose; 100% had skipping.","PGN-EDO51 was generally well-tolerated through 15 mg/kg in Phase 1; trial ID NCT06079736."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266738,"accession_number":"0000950170-23-070944","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen doses first patient in Phase 1 FREEDOM-DM1 trial; data expected in 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1 FREEDOM-DM1 trial of PGN-EDODM1 for myotonic dystrophy type 1.","Safety, transcript splicing correction, and clinical outcome data at 5 mg/kg dose expected in 2024.","UK MHRA clearance obtained, enabling enrollment in third country (US, Canada, UK).","Trial to enroll ~24 adults; single ascending doses from 5 to 20 mg/kg with safety-based escalation.","CEO James McArthur calls dosing a significant milestone toward transformative therapy for DM1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266737,"accession_number":"0000950170-23-064008","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"PepGen appoints Howard Mayer, M.D. to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Howard Mayer appointed to PepGen board effective Nov 15, 2023; fills newly created vacancy expanding board to seven members.","Dr. Mayer will receive initial option for 22,686 shares under 2022 Stock Plan; annual cash retainers $35k for board, $5k for compensation committee.","Dr. Mayer was most recently EVP, Head of R&D at Ipsen Biopharmaceuticals (2019-2023); previously SVP, CMO at Shire Pharmaceuticals.","He brings experience in rare disease clinical development and regulatory filings; will serve on Compensation Committee.","No family relationships or arrangements with other persons regarding his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266736,"accession_number":"0000950170-23-060693","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PepGen Q3 2023 net loss $23.3M; cash $129.5M; FDA clears FREEDOM-DM1 study in US","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.3M for Q3 2023, vs $18.6M in Q3 2022; R&D expenses $20.5M.","Cash and cash equivalents $129.5M as of Sept 30, 2023; runway expected into 2025.","FDA lifted clinical hold on FREEDOM-DM1 Phase 1 study; target doses 5, 10, 20 mg/kg.","FDA granted Orphan Drug Designation to PGN-EDODM1 for myotonic dystrophy type 1.","Anticipates proof-of-concept data from CONNECT1-EDO51 study in mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266735,"accession_number":"0000950170-23-052999","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on PepGen's DM1 program; US Phase 1 trial to begin","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in DM1 patients in the US.","Target dose levels in the study: 5 mg/kg, 10 mg/kg, and 20 mg/kg.","Proof-of-concept data (safety, transcript splicing, clinical outcomes) at 5 mg/kg expected in 2024.","CONNECT1-EDO51 DMD study proof-of-concept data (exon skipping, dystrophin) at 5 mg/kg expected mid-2024.","Cash and equivalents expected to fund operations into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283985,"accession_number":"0000950170-23-046722","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen receives Health Canada clearance to begin Phase 1 study of PGN-EDODM1 in DM1; FDA grants Orphan Drug Designation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Health Canada issued No Objection Letter for CTA to start FREEDOM-DM1 Phase 1 trial of PGN-EDODM1 in myotonic dystrophy type 1.","FDA granted Orphan Drug Designation to PGN-EDODM1 for the treatment of DM1.","Phase 1 study is a randomized, placebo-controlled, SAD study enrolling ~24 adults; dose escalation from 5 mg/kg to 10 mg/kg then 20 mg/kg.","Initial results from the FREEDOM-DM1 study are expected in 2024.","FDA clinical hold on US IND for PGN-EDODM1 remains; company continues working to resolve it."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283984,"accession_number":"0000950170-23-046572","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen reports preclinical data: PGN-EDODM1 corrects 99% of mis-splicing in DM1 mouse model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EDO platform delivers 25-fold higher oligonucleotide to myotube nuclei vs naked in vitro.","72% of skeletal muscle nuclei in NHPs positive for oligo after two 30 mg/kg doses.","Single dose of PGN-EDODM1 reversed 76% myotonia and corrected 68% mis-splicing in DM1 mouse.","Four doses reversed 99% myotonia and corrected 99% mis-splicing; well-tolerated.","PGN-EDO51 safety in humans: transient, mild, reversible TEAEs at 5 and 10 mg/kg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283983,"accession_number":"0001193125-23-205630","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PepGen enters ATM equity offering agreement for up to $100M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM sales agreement with Stifel to sell up to $100M of common stock at market prices.","Stifel will receive 3% commission on gross proceeds; PepGen reimburses certain legal fees.","Sales may occur on Nasdaq or in negotiated transactions, subject to company instructions.","Company is not obligated to sell any shares; agreement terminates upon sale of all shares or by mutual termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283982,"accession_number":"0000950170-23-039391","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PepGen Q2 net loss $19.5M; cash $147M; FDA clinical hold on DM1 trial continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.5M for Q2 2023 vs $17.3M YoY; R&D expense $16.9M, G&A $4.2M.","Cash and equivalents $147.0M as of June 30, 2023; runway into early 2025.","FDA clinical hold remains on IND for PGN-EDODM1 Phase 1 study; working to lift.","Phase 2 CONNECT1-EDO51 open-label MAD study dosing patients in Canada H2 2023.","Phase 2 CONNECT2-EDO51 multinational RCT expected to initiate H2 2023; initial data mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303597,"accession_number":"0000950170-23-029394","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PepGen stockholders elect Ashton and Resnick as directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Christopher Ashton elected with 22,342,065 votes for, 78,780 withheld.","Joshua Resnick elected with 19,838,946 votes for, 1,570,173 withheld.","KPMG LLP ratified as independent auditor for FY 2023: 22,610,683 for, 736 against, 0 abstentions.","Broker non-votes: 190,574 on Ashton election, 1,202,300 on Resnick election; zero on auditor ratification.","Total shares entitled to vote: 23,782,297; quorum present with 22,611,419 shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303596,"accession_number":"0000950170-23-027696","cik":1835597,"company_name":"PepGen Inc.","ticker":"PEPG","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PepGen withdraws PGN-EDODM1 Phase 1 timeline guidance pending FDA clinical hold","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Withdrawing prior guidance to initiate a Phase 1 study of PGN-EDODM1 in DM1 in H1 2023.","Awaiting official clinical hold letter from FDA; pausing additional regulatory filings to address the hold.","CEO committed to working with FDA to lift the hold and start study as quickly as feasible.","Company remains focused on advancing Phase 2 CONNECT1-EDO51 study in Duchenne muscular dystrophy, cleared by Health Canada in May 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":101678752.04605262,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-13T23:59:59+00:00|303596"}